Visiongain Publishes Cell Culture Market Report 2020-2030

02 August 2020
Pharma

Visiongain has launched a new pharma report Cell Culture Market Report 2020-2030: Prospects by Product (Instruments (Bioreactors, Cell Culture Vessels, Cell Culture Storage Equipment, Cell Culture Supporting Instruments), Consumables (Sera, Media, Reagents, Bioreactor Accessories)), Application (Biopharmaceutical/Therapeutics, Stem Cell Technology, Cancer Research, Drug Screening & Development, Tissue Engineering & Regenerative Medicine, Other applications), End user (Research Institutes, Pharmaceutical & Biotechnology Companies), and Geography.

The global cell culture market is projected to grow at a lucrative CAGR of ~xx% and anticipated to surpass USD x billion by 2030.

The growth of the cell culture market is driven by increased funding for cell-based research and increased regulatory approvals for cell-culture-based vaccines. Also, Mab demand growth and technological advances in cell culture products complement the growth of the market. However, high research costs in cell biology and lack of cell-based research infrastructure are anticipated to hamper the market growth. Low manufacturing costs are expected to provide growth opportunities for the industry in the preparation of cell culture and increased government funding for cell culture-based vaccine development.

Cell culture allows scientists to develop different types of peripheral/exterior cell colonies in their natural locations. It requires a substrate on which cell culture can grow and cell survival is achieved by supplying them with the nutrients they need to survive. In the same way, large-scale research has allowed the researchers to create a wide range of cell cultures, each requiring different survival parameters.

Cell culture is precisely a procedure for developing prokaryotic or eukaryotic cells outside their natural habitat and under-regulated laboratory conditions. This helps to study the effect on cells of medicinal drugs and bio-molecules as well as mutagenesis and carcinogenesis research studies.

The research and development in stem cells hold lucrative opportunities for the global cell culture market. In various types of ailments, stem cells find their use and application making them an essential part of medical research. In recent years, the demand for artificial organs has also increased as the technique of producing the same organs has become more efficient and reliable, making the replacement of organs much easier than before. Heavy capital investments have been made by public and private firms into stem cells and organ transplantation procedures.

In the year 2018, North America held the majority of market share in the global cell culture market. Cell culture finds its applications in numerous life science laboratories owing to the introduction & advancement of automated cell culture techniques. However, the Asia Pacific cell culture market is anticipated to witness lucrative growth rate over the forecast period owing to the growing number of CROs in the region coupled with growing expenditure from public & private entities in the research & development sector. Also, economies like Japan, China and India are offering lucrative revenue generation opportunities owing to growing healthcare expenditure, rising disposable income, and growing health awareness among other growth contributing factors.

Some of the major players operating in this industry are Becton, Dickinson and Company, Cellgenix, Corning, Danaher, Eppendorf, Fujifilm Irvine Scientific, GE Healthcare, Hi-Media Laboratories, Invivogen, Lonza Group AG, Merck KGaA, Miltenyi Biotec, Promocell, Sartorius AG, Thermo Fisher Scientific among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever